Takeda Pharmaceutical acquired Nycomed for EUR 9.6B (~$13.7B) on a cash-free, debt-free basis; announced May 19, 2011 and completed September 30, 2011, giving Takeda a major European/emerging-markets footprint (Nycomed ~EUR 2.8B revenue) and the roflumilast (Daxas) COPD franchise.